Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6oC

Transfusion

Volumn 57, Issue 4, 2017, Pages 997-1006

  Erickson, Anna ^a   Waldhaus, Katie ^a   David, Tovo ^a   Huang, Norman ^a   Rico, Salvador ^a   Corash, Laurence ^a   Mufti, Nina ^a   Benjamin, Richard J ^a  

^a CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMOTOSALEN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C3A; FIBRINOGEN; FRESH FROZEN PLASMA; PROTEIN C; PROTEIN S; PROTHROMBIN; RISTOCETIN; THROMBIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; FUROCOUMARIN DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; FREEZE THAWING; HEMOSTASIS; HUMAN; NORMAL HUMAN; PLASMA CHARACTERISTICS; STORAGE TEMPERATURE; THROMBIN TIME; THROMBOPLASTIN TIME; ULTRAVIOLET A RADIATION; BLOOD STORAGE; CRYOPRESERVATION; DISINFECTION; DRUG EFFECTS; FEMALE; MALE; PROCEDURES; RADIATION RESPONSE; TIME FACTOR; ULTRAVIOLET RADIATION;

BLOOD PRESERVATION; CRYOPRESERVATION; DISINFECTION; FEMALE; FUROCOUMARINS; HEMOSTASIS; HUMANS; MALE; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 85011705440     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13973     Document Type: Article

References (24)

1. Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. Transfusion 2016;56:2173-83. Available at: http://www.aabb.org/tm/coi/Documents/coi1113.pdf
2. AABB. Circular of Information for the use of human blood and blood components. 2013 [cited 2016 Dec 29]. Available from: http://www.aabb.org/tm/coi/Documents/coi1113.pdf.
3. Scott E, Puca K, Heraly J, Gottschall J, Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage. Transfusion 2009;49:1584-91.
4. Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001;41:570.
5. Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008;48:2525-30.
6. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007;47:120-5.
7. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000;15:169-72.
8. Leebeek FW, Schipperus MR, van Vliet HH. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion 1999;39:1150-1.
9. Irsch J, Pinkoski L, Corash L, Lin L. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function—an in vitro analysis. Vox Sang 2010;98:47-55.
10. Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion 2012;52 Suppl 1:9S-19S.
11. Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013;105:54-64.
12. van Beers JJ, van Egmond LT, Wetzels RJ, et al. Increased coagulation and fibrinolytic potential of solvent-detergent plasma: a comparative study between Omniplasma and fresh frozen plasma. Vox Sang 2016;111:33-42.
13. Holcomb JB, Donathan DP, Cotton BA, et al. Prehospital transfusion of plasma and red blood cells in trauma patients. Prehosp Emerg Care 2015;19:1-9.
14. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007;62:307-10.
15. Holcomb JB, Pati S. Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective. Hematology Am Soc Hematol Educ Program 2013;2013:656-9.
16. Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. J Trauma 2008;64Suppl2:S69-77; discussion S77-88.
17. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471-82.
18. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006;107:3753-60.
19. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
20. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005;45:1362-72.
21. Lin L, Londe H, Hanson CV, Wiesehahn G, Isaacs S, Cimino G, Corash L. Photochemical inactivation of cell-associated human immunodeficiency virus in platelet concentrates. Blood 1993;82:292-7.
22. Young G, Sørensen B, Dargaud Y, Negrier YC, Brummel-Ziedins K, Key NS, Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013;121:1944-50.
23. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011;127 Suppl 3:S21-5.
24. Norda R, Schött U, Berséus O, et al. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma. Vox Sang 2012;102:125-33.